These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24671908)

  • 1. Elvitegravir: a review of its use in adults with HIV-1 infection.
    Deeks ED
    Drugs; 2014 Apr; 74(6):687-97. PubMed ID: 24671908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
    Molina JM; Lamarca A; Andrade-Villanueva J; Clotet B; Clumeck N; Liu YP; Zhong L; Margot N; Cheng AK; Chuck SL;
    Lancet Infect Dis; 2012 Jan; 12(1):27-35. PubMed ID: 22015077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results.
    Elion R; Molina JM; Ramón Arribas López J; Cooper D; Maggiolo F; Wilkins E; Conway B; Liu YP; Margot N; Rhee M; Chuck SL; Szwarcberg J;
    J Acquir Immune Defic Syndr; 2013 Aug; 63(4):494-7. PubMed ID: 23807156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.
    Zolopa AR; Berger DS; Lampiris H; Zhong L; Chuck SL; Enejosa JV; Kearney BP; Cheng AK
    J Infect Dis; 2010 Mar; 201(6):814-22. PubMed ID: 20146631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.
    Klibanov OM
    Curr Opin Investig Drugs; 2009 Feb; 10(2):190-200. PubMed ID: 19197797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elvitegravir: a once-daily inhibitor of HIV-1 integrase.
    Wills T; Vega V
    Expert Opin Investig Drugs; 2012 Mar; 21(3):395-401. PubMed ID: 22321026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
    Taiwo B; Murphy RL; Katlama C
    Drugs; 2010 Sep; 70(13):1629-42. PubMed ID: 20731472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
    Squires K; Kityo C; Hodder S; Johnson M; Voronin E; Hagins D; Avihingsanon A; Koenig E; Jiang S; White K; Cheng A; Szwarcberg J; Cao H
    Lancet HIV; 2016 Sep; 3(9):e410-e420. PubMed ID: 27562742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrase inhibitors: a novel class of antiretroviral agents.
    Schafer JJ; Squires KE
    Ann Pharmacother; 2010 Jan; 44(1):145-56. PubMed ID: 20040702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
    Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D
    Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elvitegravir for the treatment of HIV infection.
    Reviriego C
    Drugs Today (Barc); 2014 Mar; 50(3):209-17. PubMed ID: 24696866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.
    Ramanathan S; Mathias AA; German P; Kearney BP
    Clin Pharmacokinet; 2011 Apr; 50(4):229-44. PubMed ID: 21348537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection.
    Temesgen Z
    Drugs Today (Barc); 2012 Dec; 48(12):765-71. PubMed ID: 23243633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
    Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
    AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
    da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
    J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial.
    Iwuji CC; Churchill D; Bremner S; Perry N; To Y; Lambert D; Bruce C; Waters L; Orkin C; Geretti AM
    BMC Infect Dis; 2020 Jul; 20(1):524. PubMed ID: 32689975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
    Olin JL; Spooner LM; Klibanov OM
    Ann Pharmacother; 2012 Dec; 46(12):1671-7. PubMed ID: 23136357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.